JPS58105922A - Remedy for leukemia - Google Patents

Abstract

PURPOSE:The titled drug containing a healthy human blood pharmaceutical after administering pantethine or pantethine with lecithin containing lymphatic corpuscles derived from the living body and lysolecithin as active constituents, and useful for treating leukemia with little side effects. CONSTITUTION:A remedy for leukemia containing a healthy human blood pharmaceutical after administering panthethine or the pantethine with lecitin containing lymphatic corpuscles derived from the living body and lysolecithin as active constituents. The lymphatic corpuscles of a healthy human cause the effective plasmogamy with leukemic cells in the presence of the lysolecithin, deform and destroy the leukemic cells powerfully to expel the tumorous cells. However, the lysolecithin has strong hemolytic action, and is directly unusable. The administration of the pantethine or the pantethine with lecithin increases the activity of lecithin cholesterol acyltransferase which is an in vivo enzyme, and the lysolecithin is formed in the allowable range in the living body to deform and destroy the leukemic cells.

Description

[Detailed description of the invention] The present invention relates to a therapeutic agent for leukemia.

It is characterized in that it is based on a healthy human blood product derived from the administration of a preparation containing pantethine or pantethine and lecithin as active ingredients.

Conventional chemotherapy drugs or steroid hormones have been used as medical treatments for leukemia, but they have strong side effects that sometimes make long-term administration impossible, and sometimes lead to unfortunate outcomes due to lack of efficacy or side effects. There are quite a few. Both pantethine and lecithin according to the present invention have very few side effects and can provide an effective treatment method (agent) for leukemia.

In other words, the present invention involves cell-dependent immune ability when a living body eliminates tumor cells.

In light of the fact that this immune capacity is reduced in leukemia patients and that in cell-dependent immunity, the effect is expressed by the fusion of lymphocytes, which are the main role of immune capacity, with leukemia cells, etc. The inventor has focused on improving the cell fusion property of lymphocytes in the blood of healthy people and using this blood to treat leukemia.
They discovered that healthy human blood strongly deforms and destroys white blood cells in the presence of lysolecithin, a biological substance that promotes cell fusion, and completed the present invention by applying this effect to the treatment of leukemia.

A more detailed explanation will be given below based on experimental examples.

The blood of a healthy person (a 52-year-old man) was used in the experiment.

Blood type Bg, white blood cell count 8800. Of these, 80% are lymphocytes; on the other hand, patients with chronic myeloid leukemia (
A 79-year-old woman's blood is type B, and her white blood cell count is 25.
．． 700, of which leukemia cells account for 91% and lymphocytes account for 4%. The following experiment was conducted using these.

Experiment 1 Only the blood of a leukemia patient was incubated at 87° C. for 2 hours and then stained. Among the leukemia cells, deformed and destroyed cells were searched under a microscope, but no cells were found.

Experiment 2. 25μ9 of lysolecithin in the blood of leukemia patients
Experiment 1.
When observed in the same manner as above, it was confirmed that 5% of leukemia cells were deformed and destroyed.

Experiment 3 Blood from a healthy person and blood from a leukemia patient were mixed at a ratio of 1:1 and kept at 87°C for 2 hours. Similarly, it was observed that 29% of leukemia cells were destroyed.
s was introduced.

Experiment 4 When 25 μl/- of lysolecithin was added to a mixture of healthy human blood and leukemia patient blood at a ratio of 1:1, similar observations confirmed that 79% of leukemia cells were deformed and destroyed. .

In other words, the results of Experiment 4 showed that lymphocytes from healthy individuals effectively fused with leukemia cells in the presence of lysolecithin;
This shows that it strongly deforms and destroys leukemia cells and eliminates tumor cells. However, because lysolecithin has a strong hemolytic effect, it cannot be administered directly to humans. Therefore, the present inventor separately focused on the fact that pantethine or a combination of pantethine and lecithin was administered to healthy individuals to increase lysolecithin within the body's tolerance range, and succeeded in applying this effect to the treatment of leukemia. It is something.

This will be explained below with reference to examples.

Example 1 Pantethine 1000m9 was given to a healthy person.
The blood was collected 2 hours later, mixed with the blood of a leukemia patient at a ratio of 1:1, and kept warm at 87°C for 2 hours. As a result of the same observation as in the experimental example, It was confirmed that 74% of leukemia cells were deformed and destroyed.

This means that administration of pantethine increases the activity of lecithin cholesterol acyltransferase, an enzyme in the body, and this results in the production of lysolecithin in the body (Japanese Patent Publication No. 55-2279).

This substance promotes the fusion of healthy lymphocytes and leukemia cells, indicating that the leukemia cells are deformed and destroyed.

Example 2 5 g of lecithin was orally administered to a healthy person at the same time as intravenous administration of pantethine, and blood collected 2 hours later was mixed with blood from a leukemia patient at a ratio of 1=1. As a result of observation, leukemia cells that had been deformed and destroyed were It reached 89%. This indicates that lecithin-cholesterol acyltransferase activity, which is an enzyme in the living body, increases, and because lecithin, which is a substrate for this enzyme, is present, more lysolecithin is produced and cell fusion is more strongly promoted. It shows.

From the above results, the blood of healthy people administered with pantethine alone or in combination with pantethine and lecithin has the effect of strongly deforming and destroying leukemia cells. It is certain that treatment can be performed.

In addition, the infusion device and frequency used during treatment vary depending on the patient's symptoms, but usually 1, 2, 0 ~! ioom / Adult once.

It is expected to be effective after several doses.

To accomplish the purpose of the present invention, the dosage of pantethine is 1 dose at a time.
000■ was administered intravenously, and 5g of lecithin was administered orally, but there were individual differences.

For pantethine, the dosage should be adjusted as appropriate to 2,000 ml or less from the dosage normally used for the treatment of lipid metabolic disorders, and for lecithin, the dosage should be increased or decreased from the dosage usually used for the treatment of arteriosclerosis. The amount should be increased or decreased as appropriate with a lid of around 7.5g or less. In addition, there are no particular limitations on the route of administration for both substances, such as oral or injection routes, and there is no difference from conventional drug administration.

Claims (1)

[Claims] (1) A therapeutic agent for leukemia comprising pantethine or a blood product from a healthy individual after administration of pantethine and lecithin (2) Claim 1, characterized in that the blood product contains biologically derived lymphocytes and lysolecithin as active ingredients Treatment for leukemia